Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for Utah Medical Products (UTMD) over the last 14 years, with Q4 2024 value amounting to $98000.0.

  • Utah Medical Products' Gains from Investment Securities rose 1666.67% to $98000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $98000.0, marking a year-over-year increase of 1666.67%. This contributed to the annual value of $98000.0 for FY2024, which is 1666.67% up from last year.
  • Latest data reveals that Utah Medical Products reported Gains from Investment Securities of $98000.0 as of Q4 2024, which was up 1666.67% from $84000.0 recorded in Q4 2023.
  • In the past 5 years, Utah Medical Products' Gains from Investment Securities registered a high of $98000.0 during Q4 2024, and its lowest value of $52000.0 during Q4 2021.
  • Moreover, its 5-year median value for Gains from Investment Securities was $69000.0 (2020), whereas its average is $74000.0.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 3269.23% in 2020, then tumbled by 2463.77% in 2021.
  • Quarter analysis of 5 years shows Utah Medical Products' Gains from Investment Securities stood at $69000.0 in 2020, then dropped by 24.64% to $52000.0 in 2021, then rose by 28.85% to $67000.0 in 2022, then rose by 25.37% to $84000.0 in 2023, then grew by 16.67% to $98000.0 in 2024.
  • Its last three reported values are $98000.0 in Q4 2024, $84000.0 for Q4 2023, and $67000.0 during Q4 2022.